Brain Tumors

Methods in Molecular Biology

Volumn 727, Issue , 2011, Pages 291-315

  Goldman, Serge ^a   Pirotte, Benoit J M ^a  

^a ERASME HOSPITAL   (Belgium)

Author keywords

Brain neoplasms; Carbon radioisotopes diagnostic use; Computer assisted derivatives diagnostic use; Computer assisted methionine analogs; Diagnosis; Differential; Fluorodeoxyglucose F18 diagnostic use; Glioma; Humans; Image processing; Imaging surgery; Neuronavigation; Pathology; Positron emission tomography; Radionuclide; Stereotaxic techniques

Indexed keywords

DIAGNOSTIC AGENT; FLUORODEOXYGLUCOSE F 18; RADIOPHARMACEUTICAL AGENT;

ARTICLE; BRAIN; BRAIN TUMOR; HUMAN; METHODOLOGY; PATHOLOGY; POSITRON EMISSION TOMOGRAPHY; SCINTISCANNING;

BRAIN; BRAIN NEOPLASMS; FLUORODEOXYGLUCOSE F18; HUMANS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 79956296193     PISSN: 10643745     EISSN: 19406029     Source Type: Book Series    
DOI: 10.1007/978-1-61779-062-1_16     Document Type: Chapter

References (105)

1. Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Burger, P.C., Jouvet, A., et al. (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114, 97–109.
2. Pirotte, B.J., Lubansu, A., Massager, N., Wikler, D., Goldman, S., Levivier, M. (2007) Results of positron emission tomography guidance and reassessment of the utility of and indications for stereotactic biopsy in children with infiltrative brainstem tumors. J Neurosurg 107, 392–9.
3. Mariani, L., Siegenthaler, P., Guzman, R., Friedrich, D., Fathi, A.R., Ozdoba, C., et al. (2004) The impact of tumour volume and surgery on the outcome of adults with supratentorial WHO grade II astrocytomas and oligoastrocytomas. Acta Neurochir (Wien) 146, 441–8.
4. De Witte, O., Levivier, M., Violon, P., Salmon, I., Damhaut, P., Wikler, D., Jr., et al. (1996) Prognostic value positron emission tomography with [18F]fluoro-2-deoxy-Dglucose in the low-grade glioma. Neurosurgery 39, 470–6; discussion 476–7.
5. De Witte, O., Goldberg, I., Wikler, D., Rorive, S., Damhaut, P., Monclus, M., et al. (2001) Positron emission tomography with injection of methionine as a prognostic factor in glioma. J Neurosurg 95, 746–50.
6. Daneyemez, M., Gezen, F., Canakci, Z., Kahraman, S. (1998) Radical surgery and reoperation in supratentorial malignant glial tumors. Minim Invasive Neurosurg 41, 209–13.
7. Kowalczuk, A., Macdonald, R.L., Amidei, C., Dohrmann, G., 3rd, Erickson, R.K., Hekmatpanah, J., et al. (1997) Quantitative imaging study of extent of surgical resection and prognosis of malignant astrocytomas. Neurosurgery 41, 1028–36; discussion 1036–8.
8. Yokoyama, J., Ikawa, H., Endow, M., Fuchimoto, Y., Watanabe, K., Hosoya, R., et al. (1995) The role of surgery in advanced neuroblastoma. Eur J Pediatr Surg 5, 23–6.
9. Hess, K.R. (1999) Extent of resection as a prognostic variable in the treatment of gliomas. J Neurooncol 42, 227–31.
10. Pirotte, B., Levivier, M., Goldman, S., Massager, N., Wikler, D., De Witte, O., et al. (2009) PET-guided volumetric resection of supratentorial high grade gliomas: A survival analysis in 66 consecutive patients. Neurosurgery 64(3), 471–81; discussion 481.
11. Lacroix, M., Abi-Said, D., Fourney, D.R., Gokaslan, Z.L., Shi, W., DeMonte, F., et al. (2001) A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg 95, 190–8.
12. Stummer, W., Reulen, H.J., Meinel, T., Pichlmeier, U., Schumacher, W., Tonn, J.C., et al. (2008) Extent of resection and survival in glioblastoma multiforme: identification of and adjustment for bias. Neurosurgery 62, 564–76; discussion 564–76.
13. Sanai, N., Berger, M.S. (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62, 753–64; discussion 264–6.
14. Pollack, I.F. (1999) The role of surgery in pediatric gliomas. J Neurooncol 42, 271–88.
15. Pirotte, B., Acerbi, F., Lubansu, A., Goldman, S., Brotchi, J., Levivier, M. (2007) PET imaging in the surgical management of pediatric brain tumors. Childs Nerv Syst 23, 739–51.
16. Black, P.M. (1991) Brain tumor. Part 2. N Engl J Med 324, 1555–64.
17. Black, P.M. (1991) Brain tumors. Part 1. N Engl J Med 324, 1471–6.
18. Albright, A.L. (1993) Pediatric brain tumors. CA Cancer J Clin 43, 272–88.
19. Foreman, N.K., Love, S., Gill, S.S., Coakham, H.B. (1997) Second-look surgery for incompletely resected fourth ventricle ependymomas: technical case report. Neurosurgery 40, 856–60; discussion 860.
20. Larson, D.A., Gutin, P.H., McDermott, M., Lamborn, K., Sneed, P.K., Wara, W.M., et al. (1996) Gamma knife for glioma: selection factors and survival. Int J Radiat Oncol Biol Phys 36, 1045–53.
21. Pirotte, B., Levivier, M., Morelli, D., Van Bogaert, P., Detemmerman, D., David, P., et al. (2005) Positron emission tomography for the early postsurgical evaluation of pediatric brain tumors. Childs Nerv Syst 21, 294–300.
22. Levivier, M., Goldman, S., Bidaut, L.M., Luxen, A., Stanus, E., Przedborski, S., et al. (1992) Positron emission tomographyguided stereotactic brain biopsy. Neurosurgery 31, 792–7; discussion 797.
23. Levivier, M., Goldman, S., Pirotte, B., Brucher, J.M., Baleriaux, D., Luxen, A., et al. (1995) Diagnostic yield of stereotactic brain biopsy guided by positron emission tomography with [18F]fluorodeoxyglucose. J Neurosurg 82, 445–52.
24. Chandrasoma, P.T., Smith, M.M., Apuzzo, M.L. (1989) Stereotactic biopsy in the diagnosis of brain masses: comparison of results of biopsy and resected surgical specimen. Neurosurgery 24, 160–5.
25. Feiden, W., Steude, U., Bise, K., Gundisch, O. (1991) Accuracy of stereotactic brain tumor biopsy: comparison of the histologic findings in biopsy cylinders and resected tumor tissue. Neurosurg Rev 14, 51–6.
26. Glantz, M.J., Burger, P.C., Herndon, J.E., 2nd, Friedman, A.H., Cairncross, J.G., Vick, N.A., et al. (1991) Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology 41, 1741–4.
27. Pirotte, B., Goldman, S., Van Bogaert, P., David, P., Wikler, D., Rorive, S., et al. (2005) Integration of [11C]methionine-positron emission tomographic and magnetic resonance imaging for image-guided surgical resection of infiltrative low-grade brain tumors in children. Neurosurgery 57, 128–39; discussion 128–39.
28. Pirotte, B., Goldman, S., Dewitte, O., Massager, N., Wikler, D., Lefranc, F., et al. (2006) Integrated positron emission tomography and magnetic resonance imagingguided resection of brain tumors: a report of 103 consecutive procedures. J Neurosurg 104, 238–53.
29. Wong, T.Z., van der Westhuizen, G.J., Coleman, R.E. (2002) Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 12, 615–26.
30. Paulus, W., Peiffer, J. (1989) Intratumoral histologic heterogeneity of gliomas. A quantitative study. Cancer 64, 442–7.
31. Essig, M., Metzner, R., Bonsanto, M., Hawighorst, H., Debus, J., Tronnier, V., et al. (2001) Postoperative fluid-attenuated inversion recovery MR imaging of cerebral gliomas: initial results. Eur Radiol 11, 2004–10.
32. Braun, V., Dempf, S., Tomczak, R., Wunderlich, A., Weller, R., Richter, H.P. (2000) Functional cranial neuronavigation. Direct integration of fMRI and PET data. J Neuroradiol 27, 157–63.
33. Pauleit, D., Floeth, F., Hamacher, K., Riemenschneider, M.J., Reifenberger, G., Muller, H.W., et al. (2005) O-(2-[18F] fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128, 678–87.
34. Law, M., Yang, S., Wang, H., Babb, J.S., Johnson, G., Cha, S., et al. (2003) Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 24, 1989–98.
35. Di Chiro, G. (1987) Positron emission tomography using [18F] fluorodeoxyglucose in brain tumors. A powerful diagnostic and prognostic tool. Invest Radiol 22, 360–71.
36. Alavi, J.B., Alavi, A., Chawluk, J., Kushner, M., Powe, J., Hickey, W., et al. (1988) Positron emission tomography in patients with glioma. A predictor of prognosis. Cancer 62, 1074–8.
37. Coleman, R.E., Hoffman, J.M., Hanson, M.W., Sostman, H.D., Schold, S.C. (1991) Clinical application of PET for the evaluation of brain tumors. J Nucl Med 32, 616–22.
38. Goldman, S., Levivier, M., Pirotte, B., Brucher, J.M., Wikler, D., Damhaut, P., et al. (1996) Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 78, 1098–106.
39. Chen, W. (2007) Clinical applications of PET in brain tumors. J Nucl Med 48, 1468–81.
40. Ishizu, K., Sadato, N., Yonekura, Y., Nishizawa, S., Magata, Y., Tamaki, N., et al. (1994) Enhanced detection of brain tumors by [18F]fluorodeoxyglucose PET with glucose loading. J Comput Assist Tomogr 18, 12–5.
41. Spence, A.M., Muzi, M., Mankoff, D.A., O’Sullivan, S.F., Link, J.M., Lewellen, T.K., et al. (2004) 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med 45, 1653–9.
42. Becherer, A., Karanikas, G., Szabo, M., Zettinig, G., Asenbaum, S., Marosi, C., et al. (2003) Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging 30, 1561–7.
43. Weber, W.A., Wester, H.J., Grosu, A.L., Herz, M., Dzewas, B., Feldmann, H.J., et al. (2000) O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med 27, 542–9.
44. Lahoutte, T., Caveliers, V., Camargo, S.M., Franca, R., Ramadan, T., Veljkovic, E., et al. (2004) SPECT and PET amino acid tracer influx via system L (h4F2hc-hLAT1) and its transstimulation. J Nucl Med 45, 1591–6.
45. Laique, S., Egrise, D., Monclus, M., Schmitz, F., Garcia, C., Lemaire, C., et al. (2006) L-amino acid load to enhance PET differentiation between tumor and inflammation: an in vitro study on (18)F-FET uptake. Contrast Media Mol Imaging 1, 212–20.
46. Sadeghi, N., Salmon, I., Decaestecker, C., Levivier, M., Metens, T., Wikler, D., et al. (2007) Stereotactic comparison among cerebral blood volume, methionine uptake, and histopathology in brain glioma. AJNR Am J Neuroradiol 28, 455–61.
47. Goldman, S., Levivier, M., Pirotte, B., Brucher, J.M., Wikler, D., Damhaut, P., et al. (1997) Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 38, 1459–62.
48. Chen, W., Delaloye, S., Silverman, D.H., Geist, C., Czernin, J., Sayre, J., et al. (2007) Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol 25, 4714–21.
49. Hatakeyam, T., Kawai, N., Nishiyama, Y., Yamamoto, Y., Sasakawa, Y., Ichikawa, T., et al. (2008) (11)C-methionine (MET) and (18)F-fluorothymidine (FLT) PET in patients with newly diagnosed glioma. Eur J Nucl Med Mol Imaging 35, 2009–17.
50. Saga, T., Kawashima, H., Araki, N., Takahashi, J.A., Nakashima, Y., Higashi, T., et al. (2006) Evaluation of primary brain tumors with FLT-PET: usefulness and limitations. Clin Nucl Med 31, 774–80.
51. Kwee, S.A., Ko, J.P., Jiang, C.S., Watters, M.R., Coel, M.N. (2007) Solitary brain lesions enhancing at MR imaging: evaluation with fluorine 18 fluorocholine PET. Radiology 244, 557–65.
52. Xiangsong, Z., Changhong, L., Weian, C., Dong, Z. (2006) PET Imaging of cerebral astrocytoma with 13N-ammonia. J Neurooncol 78, 145–51.
53. Mineura, K., Sasajima, T., Kowada, M., Ogawa, T., Hatazawa, J., Shishido, F., et al. (1994) Perfusion and metabolism in predicting the survival of patients with cerebral gliomas. Cancer 73, 2386–94.
54. Sadeghi, N., D’Haene, N., Decaestecker, C., Levivier, M., Metens, T., Maris, C., et al. (2008) Apparent diffusion coefficient and cerebral blood volume in brain gliomas: relation to tumor cell density and tumor microvessel density based on stereotactic biopsies. AJNR Am J Neuroradiol 29, 476–82.
55. Bruehlmeier, M., Roelcke, U., Schubiger, P.A., Ametamey, S.M. (2004) Assessment of hypoxia and perfusion in human brain tumors using PET with 18F-fluoromisonidazole and 15O-H2O. J Nucl Med 45, 1851–9.
56. Cher, L.M., Murone, C., Lawrentschuk, N., Ramdave, S., Papenfuss, A., Hannah, A., et al. (2006) Correlation of hypoxic cell fraction and angiogenesis with glucose metabolic rate in gliomas using 18F-fluoromisonidazole, 18F-FDG PET, and immunohistochemical studies. J Nucl Med 47, 410–8.
57. Spence, A.M., Muzi, M., Swanson, K.R., O’Sullivan, F., Rockhill, J.K., Rajendran, J.G., et al. (2008) Regional hypoxia in glioblastoma multiforme quantified with 18F] fluoromisonidazole positron emission tomography before radiotherapy: correlation with time to progression and survival. Clin Cancer Res 14, 2623–30.
58. Ullrich, R., Backes, H., Li, H., Kracht, L., Miletic, H., Kesper, K., et al. (2008) Glioma proliferation as assessed by 3’-fluoro-3’deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma. Clin Cancer Res 14, 2049–55.
59. Tang, B.N., Sadeghi, N., Branle, F., De Witte, O., Wikler, D., Goldman, S. (2005) Semi-quantification of methionine uptake and flair signal for the evaluation of chemotherapy in low-grade oligodendroglioma. J Neurooncol 71, 161–8.
60. Daumas-Duport, C., Scheithauer, B.W., Kelly, P.J. (1987) A histologic and cytologic method for the spatial definition of gliomas. Mayo Clin Proc 62, 435–49.
61. Kelly, P.J., Daumas-Duport, C., Scheithauer, B.W., Kall, B.A., Kispert, D.B. (1987) Stereotactic histologic correlations of computed tomography-and magnetic resonance imaging-defined abnormalities in patients with glial neoplasms. Mayo Clin Proc 62, 450–9.
62. Kracht, L.W., Miletic, H., Busch, S., Jacobs, A.H., Voges, J., Hoevels, M., et al. (2004) Delineation of brain tumor extent with [11C]L-methionine positron emission tomography: local comparison with stereotactic histopathology. Clin Cancer Res 10, 7163–70.
63. Tang, B.N., Van Simaeys, G., Devriendt, D., Sadeghi, N., Dewitte, O., Massager, N., et al. (2008) Three-dimensional Gaussian model to define brain metastasis limits on (11) C-methionine PET. Radiother Oncol 89, 270–7.
64. Delbeke, D., Meyerowitz, C., Lapidus, R.L., Maciunas, R.J., Jennings, M.T., Moots, P.L., et al. (1995) Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 195, 47–52.
65. Rosenfeld, S.S., Hoffman, J.M., Coleman, R.E., Glantz, M.J., Hanson, M.W., Schold, S.C. (1992) Studies of primary central nervous system lymphoma with fluorine-18fluorodeoxyglucose positron emission tomography. J Nucl Med 33, 532–6.
66. Kawai, N., Nishiyama, Y., Miyake, K., Tamiya, T., Nagao, S. (2005) Evaluation of tumor FDG transport and metabolism in primary central nervous system lymphoma using [18F]fluorodeoxyglucose (FDG) positron emission tomography (PET) kinetic analysis. Ann Nucl Med 19, 685–90.
67. Karantanis, D., O’Eill, B.P., Subramaniam, R.M., Witte, R.J., Mullan, B.P., Nathan, M.A., et al. (2007) 18F-FDG PET-CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun 28, 834–41.
68. Pirotte, B., Levivier, M., Goldman, S., Brucher, J.M., Brotchi, J., Hildebrand, J. (1997) Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the literature. J Neurooncol 32, 63–9.
69. Bergstrom, M., Ericson, K., Hagenfeldt, L., Mosskin, M., von Holst, H., Noren, G., et al. (1987) PET study of methionine accumulation in glioma and normal brain tissue: competition with branched chain amino acids. J Comput Assist Tomogr 11, 208–13.
70. Derlon, J.M., Bourdet, C., Bustany, P., Chatel, M., Theron, J., Darcel, F., et al. (1989) [11C]L-methionine uptake in gliomas. Neurosurgery 25, 720–8.
71. Mosskin, M., von Holst, H., Bergstrom, M., Collins, V.P., Eriksson, L., Johnstrom, P., et al. (1987) Positron emission tomography with 11C-methionine and computed tomography of intracranial tumours compared with histopathologic examination of multiple biopsies. Acta Radiol 28, 673–81.
72. Kaplan, A.M., Bandy, D.J., Manwaring, K.H., Chen, K., Lawson, M.A., Moss, S.D., et al. (1999) Functional brain mapping using positron emission tomography scanning in preoperative neurosurgical planning for pediatric brain tumors. J Neurosurg 91, 797–803.
73. Utriainen, M., Metsahonkala, L., Salmi, T.T., Utriainen, T., Kalimo, H., Pihko, H., et al. (2002) Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography. Cancer 95, 1376–86.
74. Borgwardt, L., Hojgaard, L., Carstensen, H., Laursen, H., Nowak, M., Thomsen, C., et al. (2005) Increased fluorine-18 2-fluoro2-deoxy-D-glucose (FDG) uptake in childhood CNS tumors is correlated with malignancy grade: a study with FDG positron emission tomography/magnetic resonance imaging coregistration and image fusion. J Clin Oncol 23, 3030–7.
75. Pirotte, B., Lubansu, A., Massager, N., Wikler, D., Van Bogaert, P., Levivier, M., et al. (2010) Clinical interest of integrating positron emission tomography imaging in the workup of 55 children with incidentally diagnosed brain lesions. J Neurosurg Pediatr 5, 479–85.
76. Sasaki, M., Kuwabara, Y., Yoshida, T., Fukumura, T., Morioka, T., Nishio, S., et al. (1998) Carbon-11-methionine PET in focal cortical dysplasia: a comparison with fluorine18-FDG PET and technetium-99m-ECD SPECT. J Nucl Med 39, 974–7.
77. De Witte, O., Lefranc, F., Levivier, M., Salmon, I., Brotchi, J., Goldman, S. (2000) FDG-PET as a prognostic factor in high-grade astrocytoma. J Neurooncol 49, 157–63.
78. Ribom, D., Eriksson, A., Hartman, M., Engler, H., Nilsson, A., Langstrom, B., et al. (2001) Positron emission tomography (11) C-methionine and survival in patients with low-grade gliomas. Cancer 92, 1541–9.
79. Kim, S., Chung, J.K., Im, S.H., Jeong, J.M., Lee, D.S., Kim, D.G., et al. (2005) 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 32, 52–9.
80. Floeth, F.W., Pauleit, D., Sabel, M., Stoffels, G., Reifenberger, G., Riemenschneider, M.J., et al. (2007) Prognostic value of O-(2-18F-fluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48, 519–27.
81. Glantz, M.J., Hoffman, J.M., Coleman, R.E., Friedman, A.H., Hanson, M.W., Burger, P.C., et al. (1991) Identification of early recurrence of primary central nervous system tumors by [18F]fluorodeoxyglucose positron emission tomography. Ann Neurol 29, 347–55.
82. Patronas, N.J., Di Chiro, G., Brooks, R.A., DeLaPaz, R.L., Kornblith, P.L., Smith, B.H., et al. (1982) Work in progress: [18F] fluorodeoxyglucose and positron emission tomography in the evaluation of radiation necrosis of the brain. Radiology 144, 885–9.
83. Chao, S.T., Suh, J.H., Raja, S., Lee, S.Y., Barnett, G. (2001) The sensitivity and specificity of FDG PET in distinguishing recurrent brain tumor from radionecrosis in patients treated with stereotactic radiosurgery. Int J Cancer 96, 191–7.
84. Mehrkens, J.H., Popperl, G., Rachinger, W., Herms, J., Seelos, K., Tatsch, K., et al. (2008) The positive predictive value of O-(2-[18F]fluoroethyl)-L-tyrosine (FET) PET in the diagnosis of a glioma recurrence after multimodal treatment. J Neurooncol 88, 27–35.
85. Terakawa, Y., Tsuyuguchi, N., Iwai, Y., Yamanaka, K., Higashiyama, S., Takami, T., et al. (2008) Diagnostic accuracy of 11C-methionine PET for differentiation of recurrent brain tumors from radiation necrosis after radiotherapy. J Nucl Med 49, 694–9.
86. Chung, J.K., Kim, Y.K., Kim, S.K., Lee, Y.J., Paek, S., Yeo, J.S., et al. (2002) Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo-or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging 29, 176–82.
87. Bergstrom, M., Muhr, C., Lundberg, P.O., Bergstrom, K., Lundqvist, H., Langstrom, B. (1986) Amino acid metabolism in pituitary adenomas. Acta Radiol Suppl 369, 412–4.
88. Bergstrom, M., Muhr, C., Lundberg, P.O., Langstrom, B. (1991) PET as a tool in the clinical evaluation of pituitary adenomas. J Nucl Med 32, 610–5.
89. Tang, B.N., Levivier, M., Heureux, M., Wikler, D., Massager, N., Devriendt, D., et al. (2006) 11C-methionine PET for the diagnosis and management of recurrent pituitary adenomas. Eur J Nucl Med Mol Imaging 33, 169–78.
90. Francavilla, T.L., Miletich, R.S., Di Chiro, G., Patronas, N.J., Rizzoli, H.V., Wright, D.C. (1989) Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 24, 1–5.
91. Popperl, G., Gotz, C., Rachinger, W., Gildehaus, F.J., Tonn, J.C., Tatsch, K. (2004) Value of O-(2-[18F]fluoroethyl)L-tyrosine PET for the diagnosis of recurrent glioma. Eur J Nucl Med Mol Imaging 31, 1464–70.
92. Chen, W., Silverman, D.H., Delaloye, S., Czernin, J., Kamdar, N., Pope, W., et al. (2006) 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47, 904–11.
93. Hillner, B.E., Siegel, B.A., Shields, A.F., Liu, D., Gareen, I.F., Hanna, L., et al. (2008) The impact of positron emission tomography (PET) on expected management during cancer treatment: findings of the National Oncologic PET Registry. Cancer 115(2), 410–8.
94. Popperl, G., Gotz, C., Rachinger, W., Schnell, O., Gildehaus, F.J., Tonn, J.C., et al. (2006) Serial O-(2-[(18)F]fluoroethyl)-L:-tyrosine PET for monitoring the effects of intracavitary radioimmunotherapy in patients with malignant glioma. Eur J Nucl Med Mol Imaging 33, 792–800.
95. Valk, P.E., Budinger, T.F., Levin, V.A., Silver, P., Gutin, P.H., Doyle, W.K. (1988) PET of malignant cerebral tumors after interstitial brachytherapy. Demonstration of metabolic activity and correlation with clinical outcome. J Neurosurg 69, 830–8.
96. Popperl, G., Goldbrunner, R., Gildehaus, F.J., Kreth, F.W., Tanner, P., Holtmannspotter, M., et al. (2005) O-(2-[18F] fluoroethyl)-L-tyrosine PET for monitoring the effects of convection-enhanced delivery of paclitaxel in patients with recurrent glioblastoma. Eur J Nucl Med Mol Imaging 32, 1018–25.
97. Rozental, J.M., Levine, R.L., Nickles, R.J., Dobkin, J.A. (1989) Glucose uptake by gliomas after treatment. A positron emission tomographic study. Arch Neurol 46, 1302–7.
98. De Witte, O., Hildebrand, J., Luxen, A., Goldman, S. (1994) Acute effect of carmustine on glucose metabolism in brain and glioblastoma. Cancer 74, 2836–42.
99. Pirotte, B., Goldman, S., Massager, N., David, P., Wikler, D., Vandesteene, A., et al. (2004) Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 45, 1293–8.
100. Pirotte, B., Goldman, S., David, P., Wikler, D., Damhaut, P., Vandesteene, A., et al. (1997) Stereotactic brain biopsy guided by positron emission tomography (PET) with [F-18]fluorodeoxyglucose and [C-11]methionine Acta Neurochir Suppl 68, 133–8.
101. Massager, N., David, P., Goldman, S., Pirotte, B., Wikler, D., Salmon, I., et al. (2000) Combined magnetic resonance imagingand positron emission tomographyguided stereotactic biopsy in brainstem mass lesions: diagnostic yield in a series of 30 patients J Neurosurg 93, 951–7.
102. Levivier, M., Massager, N., Wikler, D., Devriendt, D., Goldman, S. (2007) Integration of functional imaging in radiosurgery: The Example of PET Scan Prog Neurol Surg 20, 68–81.
103. Levivier, M., Massager, N., Wikler, D., Lorenzoni, J., Ruiz, S., Devriendt, D., et al. (2004) Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification J Nucl Med 45, 1146–54.
104. Levivier, M., Wikler, D., Jr., Massager, N., David, P., Devriendt, D., Lorenzoni, J., et al. (2002) The integration of metabolic imaging in stereotactic procedures including radiosurgery: a review J Neurosurg 97, 542–50.
105. Torii, K., Tsuyuguchi, N., Kawabe, J., Sunada, I., Hara, M., Shiomi, S. (2005) Correlation of amino-acid uptake using methionine PET and histological classifications in various gliomas Ann Nucl Med 19(8), 677–83.